

II. REMARKS

Amendment of the claims

Claims 1-12 are canceled, claim 13 is amended, and new claims 14-27 are submitted.

Independent claim 13 is amended to identify the abbreviated term "SAP" as "serum amyloid P component (SAP)," as described on page 2, line 8. Canceled claims 1-12 are Swiss-type claims directed to a "use" of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject. Canceled claims 1-12 are replaced by new claims 14-27, which are directed to a disclosed method for treatment or prevention of osteoarthritis in a subject comprising administering to the subject a therapeutically effective amount of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject as described in canceled claims 2-12. The amendment does not submit new matter.

III. CONCLUSION

The applicants respectfully request consideration and allowance of the present application.

Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP



Date: February 1, 2006

Thomas A. Cawley, Jr., Ph.D.

Reg. No. 40944

Tel. No. (703) 770-7744

Fax No. (703) 770-7900

P.O. Box 10500
McLean, VA 22102
(703) 770-7900